{"protocolSection": {"identificationModule": {"nctId": "NCT02170363", "orgStudyIdInfo": {"id": "TC02212014"}, "organization": {"fullName": "Abbott Medical Devices", "class": "INDUSTRY"}, "briefTitle": "HeartMate 3\u2122 CE Mark Clinical Investigation Plan", "officialTitle": "HeartMate 3\u2122 CE Mark Clinical Investigation Plan", "acronym": "HM3 CE Mark"}, "statusModule": {"statusVerifiedDate": "2022-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-06"}, "primaryCompletionDateStruct": {"date": "2015-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-03-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-06-19", "studyFirstSubmitQcDate": "2014-06-19", "studyFirstPostDateStruct": {"date": "2014-06-23", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-04-21", "resultsFirstSubmitQcDate": "2017-08-03", "resultsFirstPostDateStruct": {"date": "2018-02-15", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-06-23", "lastUpdatePostDateStruct": {"date": "2022-06-27", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Abbott Medical Devices", "class": "INDUSTRY"}, "collaborators": [{"name": "Center for Life Sciences", "class": "UNKNOWN"}, {"name": "Emergo", "class": "UNKNOWN"}, {"name": "KCRI", "class": "OTHER"}, {"name": "Thoratec Corporation", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this clinical investigation is to evaluate the performance and safety of the HeartMate 3 Left Ventricular Assist System (HM3 LVAS) To support obtaining CE Mark for the HM3 LVAS in Europe, a multi-center clinical study will be conducted in multiple countries. The clinical study will be conducted in compliance with the Declaration of Helsinki, ICH/GCP and EN ISO 14155:2011 Requirements for Clinical Investigations and in accordance with country-specific requirements, under one clinical study protocol.\n\nThis study will evaluate the performance of the HM3 LVAS, side effects and undesirable conditions within acceptable risks and weigh them against the intended performance of HM3 LVAS in accordance with Essential Requirements 2, 5 and 16 of the Active Implantable Medical Device Directive 90/385/EEC (AIMDD)."}, "conditionsModule": {"conditions": ["Advanced Refractory Left Ventricular Heart Failure"], "keywords": ["Heart Failure", "Ventricular Dysfunction", "Cardiomyopathies", "Heart Disease", "Cardiovascular Disease", "Heart-assist devices", "Thoratec Corporation"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 50, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "HeartMate 3", "type": "EXPERIMENTAL", "description": "Left Ventricular Assist System (LVAS) to be used on Subjects with advanced refractory left ventricular heart failure", "interventionNames": ["Device: Left Ventricular Assist System (LVAS)"]}], "interventions": [{"type": "DEVICE", "name": "Left Ventricular Assist System (LVAS)", "description": "Implantation of left ventricular assist device for hemodynamic support", "armGroupLabels": ["HeartMate 3"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Survival", "description": "Comparison of survival at 6 months of Left Ventricular Assist Device (LVAD) support to a performance goal established using matched HeartMate II INTERMACS data", "timeFrame": "6 months"}], "secondaryOutcomes": [{"measure": "Quality of Life (EQ-5D-5L)", "description": "The EQ-5D-5L is a standardized measure of health status developed by the EuroQol Group. Patients describe their perceived health status using an analog scale with 0 as the worst health the patient can imagine and 100 as the best health (Visual Analog Score). The patients' scores at one, three and six months were compared to their baseline scores and the resulting positive scores indicated improved quality of life.", "timeFrame": "Baseline, Month 1, Month 3, Month 6"}, {"measure": "Functional Status - Six Minute Walk Test (6MWT)", "description": "The Six Minute Walk Test(6MWT)measures the distance that a patient can walk in a period of 6 minutes. The distance walked is measured in meters. This test measures the patients' functional status. The more meters a patient can walk over baseline indicates improvement in functional status.", "timeFrame": "Baseline, Month 1, Month 3, Month 6"}, {"measure": "Functional Status - New York Heart Association (NYHA) Classification", "description": "NYHA classification relates symptoms to every day activities and patients quality of life. Class 1 = no limitations on physical activity Class 2 - slight limitation of physical activity Class 3 - marked limitation of physical activity Class 4 = unable to carry out any physical activity without discomfort", "timeFrame": "Baseline, Month 1, Month 3, Month 6"}, {"measure": "All Adverse Events", "description": "Frequency of pre-defined anticipated adverse events", "timeFrame": "As they occurred, Baseline through 180 Days"}, {"measure": "Device Malfunctions", "description": "Frequency and incidence of device malfunction", "timeFrame": "As they occurred, Baseline through 180 Days; Subjects that remain ongoing after 6 months will continue to be followed to 24 months post-implant or outcome"}, {"measure": "Reoperations", "description": "Frequency of reoperations", "timeFrame": "As they occurred, Baseline through 180 Days"}, {"measure": "Rehospitalizations", "description": "Frequency and incidence of rehospitalizations", "timeFrame": "As they occurred, Baseline through 180 Days"}, {"measure": "Stroke Free Survival", "description": "Percentage of participants free of debilitating stroke (Modified Rankin Score \\> 3)", "timeFrame": "6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Patient or legal representative has signed Informed Consent Form (ICF)\n2. Age \u2265 18 years\n3. BSA \u2265 1.2 m2\n4. NYHA IIIB or IV OR ACC/AHA Stage D\n5. LVEF \u2264 25%\n6. CI \u2264 2.2 L/min/m2, while not on inotropes\n7. Patients must also meet one of the following:\n\n   - On Optimal Medical Management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and are failing to respond,\n\n   OR\n\n   - In NYHA class IIIB or IV heart failure for at least 14 days AND dependent on intraaortic balloon pump (IABP) for at least 7 days,\n\n   OR\n\n   - Inotrope dependent/unable to wean from inotropes\n\n   OR\n\n   - Listed for Transplant\n8. Females of child bearing age must agree to use adequate contraception\n\nExclusion Criteria:\n\n1. Etiology of HF due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis or restrictive cardiomyopathy\n2. Technical obstacles which pose an inordinately high surgical risk, in the judgment of the investigator\n3. Existence of ongoing mechanical circulatory support (MCS) other than IABP\n4. Positive pregnancy test if of childbearing potential\n5. Lactating mothers\n6. Presence of mechanical aortic cardiac valve that will not be converted to a bioprosthesis at the time of LVAD implant\n7. History of any organ transplant\n8. Platelet count \\< 100,000 x 103/L (\\< 100,000/ml)\n9. Psychiatric disease/disorder, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAS management\n10. History of confirmed, untreated AAA \\> 5 cm in diameter\n11. Presence of an active, uncontrolled infection\n12. Intolerance to anticoagulant or antiplatelet therapies or any other peri/post-operative therapy the investigator will require based upon the patients' health status\n13. Presence of any one of the following risk factors for indications of severe end organ dysfunction or failure:\n\n    1. An INR \u2265 2.5 not due to anticoagulation therapy\n    2. Total bilirubin \\> 43 umol/L (2.5 mg/dl), shock liver, or biopsy proven liver cirrhosis\n    3. History of severe chronic obstructive pulmonary disease (COPD) defined by FEV1/FVC \\< 0.7, or FEV1 \\<50% predicted\n    4. Fixed pulmonary hypertension with a most recent PVR \u2265 8 Wood units that is unresponsive to pharmacologic intervention\n    5. History of stroke within 90 days prior to enrollment, or a history of cerebrovascular disease with significant (\\> 80%) carotid artery stenosis\n    6. Serum creatinine \u2265221umol/L (2.5 mg/dl) or the need for chronic renal replacement therapy\n    7. Significant peripheral vascular disease (PVD) accompanied by rest pain or extremity ulceration\n14. Patient has moderate to severe aortic insufficiency without plans for correction during pump implant\n15. Pre albumin \\< 150 mg/L, or Albumin \\< 30g/L (3 g/dL)\n16. Planned Bi-VAD support prior to enrollment\n17. Patient has known hypo or hyper coagulable states such as disseminated intravascular coagulation and heparin induced thrombocytopenia\n18. Participation in any other clinical investigation that is likely to confound study results or affect the study\n19. Any condition other than HF that could limit survival to less than 24 months", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Carlo Gazzola, B. Sc.", "affiliation": "Abbott", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "The Alfred Hospital", "city": "Melbourne", "state": "Victoria", "zip": "3181", "country": "Australia", "geoPoint": {"lat": -37.814, "lon": 144.96332}}, {"facility": "AKH Medical University of Vienna", "city": "Vienna", "zip": "A-1090", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "Toronto General Hospital", "city": "Toronto", "state": "Ontario", "zip": "M5G-2C4", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Institute for Clinical and Experimental Medicine (IKEM)", "city": "Prague", "zip": "4", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"facility": "Herz- und Diabeteszentrum NRW Thorax- und Kardiovaskularchirurgie Clinic", "city": "Bad Oeynhausen", "zip": "32545", "country": "Germany", "geoPoint": {"lat": 52.20699, "lon": 8.80365}}, {"facility": "Deutsches Herzzentrum Berlin", "city": "Berlin", "zip": "13353", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Universitats-Herzzentrum Freiburg", "city": "Freiburg", "zip": "79106", "country": "Germany", "geoPoint": {"lat": 47.9959, "lon": 7.85222}}, {"facility": "Medizinische Hochschule Hannover", "city": "Hannover", "zip": "30625", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Herzentrum Leipzig GmbH", "city": "Leipzig", "zip": "04280", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "National Research Center for Cardiac Surgery", "city": "Astana", "zip": "010000", "country": "Kazakhstan", "geoPoint": {"lat": 51.1801, "lon": 71.44598}}]}, "referencesModule": {"references": [{"pmid": "26670056", "type": "RESULT", "citation": "Netuka I, Sood P, Pya Y, Zimpfer D, Krabatsch T, Garbade J, Rao V, Morshuis M, Marasco S, Beyersdorf F, Damme L, Schmitto JD. Fully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF: A Multicenter Study. J Am Coll Cardiol. 2015 Dec 15;66(23):2579-2589. doi: 10.1016/j.jacc.2015.09.083."}, {"pmid": "30052304", "type": "DERIVED", "citation": "Schmitto JD, Pya Y, Zimpfer D, Krabatsch T, Garbade J, Rao V, Morshuis M, Beyersdorf F, Marasco S, Sood P, Damme L, Netuka I. Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3 CE Mark Study. Eur J Heart Fail. 2019 Jan;21(1):90-97. doi: 10.1002/ejhf.1284. Epub 2018 Jul 27."}, {"pmid": "28376837", "type": "DERIVED", "citation": "Krabatsch T, Netuka I, Schmitto JD, Zimpfer D, Garbade J, Rao V, Morshuis M, Beyersdorf F, Marasco S, Damme L, Pya Y. Heartmate 3 fully magnetically levitated left ventricular assist device for the treatment of advanced heart failure -1 year results from the Ce mark trial. J Cardiothorac Surg. 2017 Apr 4;12(1):23. doi: 10.1186/s13019-017-0587-3."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The data presented in this record includes all 50 patients followed through to the 6-month primary endpoint.", "recruitmentDetails": "50 patients were recruited at 10 cardiac transplant centers and implanted between June 25, 2014, and November 27, 2014", "groups": [{"id": "FG000", "title": "HeartMate 3", "description": "HeartMate 3 Left Ventricular Assist System (HM3 LVAS) used for advanced refractory left ventricular heart failure (50 Subjects in the Study Cohort)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Followed to the 6-Month Primary Endpoint", "numSubjects": "50"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "HeartMate 3", "description": "HeartMate 3 Left Ventricular Assist System (HM3 LVAS) used for advanced refractory left ventricular heart failure (50 Subjects in the Study Cohort)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "50"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.9", "spread": "13.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "5"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "45"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Canada", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}]}]}, {"title": "Austria", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}]}]}, {"title": "Czech Republic", "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}]}]}, {"title": "Australia", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}]}]}, {"title": "Kazakhstan", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}]}]}, {"title": "Germany", "categories": [{"measurements": [{"groupId": "BG000", "value": "21"}]}]}]}, {"title": "Body Surface Area", "description": "Body Surface Area (BSA) calculated from patients height and weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "M^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2", "spread": "0.2"}]}]}]}, {"title": "Cardiac Index", "description": "Cardiac index (CI) is a hemodynamic parameter that relates the cardiac output (CO) from left ventricle in one minute to body surface area (BSA), thus relating heart performance to the size of the individual. Values less than 2.2 L/min/m\\^2 indicate that the patient may be in cardiogenic shock.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "L/min/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1.8", "spread": "0.5"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Survival", "description": "Comparison of survival at 6 months of Left Ventricular Assist Device (LVAD) support to a performance goal established using matched HeartMate II INTERMACS data", "populationDescription": "All 50 patients were analyzed when the last patient reached the 6-month primary endpoint on May 26, 2015", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "97.5% Confidence Interval", "unitOfMeasure": "Percentage of Participants who Survived", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "HeartMate 3", "description": "HeartMate 3 Left Ventricular Assist System (HM3 LVAS) used for advanced refractory left ventricular heart failure (50 Subjects in the Study Cohort)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "92", "lowerLimit": "83", "upperLimit": "97"}]}]}]}, {"type": "SECONDARY", "title": "Quality of Life (EQ-5D-5L)", "description": "The EQ-5D-5L is a standardized measure of health status developed by the EuroQol Group. Patients describe their perceived health status using an analog scale with 0 as the worst health the patient can imagine and 100 as the best health (Visual Analog Score). The patients' scores at one, three and six months were compared to their baseline scores and the resulting positive scores indicated improved quality of life.", "populationDescription": "Patients alive and capable of performing the test at 6 months", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Units on a EQ-5D-5L Score scale", "timeFrame": "Baseline, Month 1, Month 3, Month 6", "groups": [{"id": "OG000", "title": "HeartMate 3", "description": "Left Ventricular Assist System (LVAS) to be used on Subjects with advanced refractory left ventricular heart failure"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "50", "lowerLimit": "12", "upperLimit": "90"}]}]}, {"title": "Month 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "60", "lowerLimit": "10", "upperLimit": "95"}]}]}, {"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "70", "lowerLimit": "30", "upperLimit": "100"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "40"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "75", "lowerLimit": "29", "upperLimit": "100"}]}]}]}, {"type": "SECONDARY", "title": "Functional Status - Six Minute Walk Test (6MWT)", "description": "The Six Minute Walk Test(6MWT)measures the distance that a patient can walk in a period of 6 minutes. The distance walked is measured in meters. This test measures the patients' functional status. The more meters a patient can walk over baseline indicates improvement in functional status.", "populationDescription": "Only patients alive, capable and willing to perform test are included.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "meters", "timeFrame": "Baseline, Month 1, Month 3, Month 6", "groups": [{"id": "OG000", "title": "HeartMate 3", "description": "Left Ventricular Assist System (LVAS) to be used on Subjects with advanced refractory left ventricular heart failure"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "236", "lowerLimit": "5", "upperLimit": "550"}]}]}, {"title": "Month 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "260", "lowerLimit": "21.1", "upperLimit": "582"}]}]}, {"title": "Month 3", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "47"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "375", "lowerLimit": "35", "upperLimit": "671"}]}]}, {"title": "Month 6", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "385", "lowerLimit": "70", "upperLimit": "705"}]}]}]}, {"type": "SECONDARY", "title": "Functional Status - New York Heart Association (NYHA) Classification", "description": "NYHA classification relates symptoms to every day activities and patients quality of life. Class 1 = no limitations on physical activity Class 2 - slight limitation of physical activity Class 3 - marked limitation of physical activity Class 4 = unable to carry out any physical activity without discomfort", "populationDescription": "Only patients alive, capable and willing to perform test are included.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline, Month 1, Month 3, Month 6", "groups": [{"id": "OG000", "title": "HeartMate 3", "description": "Left Ventricular Assist System (LVAS) to be used on Subjects with advanced refractory left ventricular heart failure\n\nLeft Ventricular Assist System (LVAS): Implantation of left ventricular assist device for hemodynamic support"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"title": "Baseline NYHA I or II", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Baseline NYHA III or IV", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "100"}]}]}, {"title": "Month 1 NYHA I or II", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "64"}]}]}, {"title": "Month 1 NYHA III or IV", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}]}]}, {"title": "Month 3 NYHA 1 or II", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "81"}]}]}, {"title": "Month 3 NYHA III or IV", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "19"}]}]}, {"title": "Month 6 NYHA I or II", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "83"}]}]}, {"title": "Month 6 NYHA III or IV", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}]}]}]}, {"type": "SECONDARY", "title": "All Adverse Events", "description": "Frequency of pre-defined anticipated adverse events", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "% of Participants with Adverse Events", "timeFrame": "As they occurred, Baseline through 180 Days", "groups": [{"id": "OG000", "title": "HeartMate 3", "description": "HeartMate 3 Left Ventricular Assist System (HM3 LVAS) used for advanced refractory left ventricular heart failure (50 Subjects in the Study Cohort)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"title": "Bleeding", "categories": [{"measurements": [{"groupId": "OG000", "value": "38"}]}]}, {"title": "Bleeding requiring surgery", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}]}]}, {"title": "Gastrointestinal bleeding", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}]}]}, {"title": "Cardiac Arrhythmia", "categories": [{"measurements": [{"groupId": "OG000", "value": "34"}]}]}, {"title": "Pericardial fluid", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Internal device malfunction", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}]}]}, {"title": "Pump thrombosis", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "External device malfunctions", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}]}]}, {"title": "Hemolysis", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Hepatic dysfunction", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Hypertension", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Any infection", "categories": [{"measurements": [{"groupId": "OG000", "value": "36"}]}]}, {"title": "Infection - sepsis", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}]}]}, {"title": "Infection - driveline", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}]}]}, {"title": "Myocardial infarction", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Any stroke", "categories": [{"measurements": [{"groupId": "OG000", "value": "12"}]}]}, {"title": "Stroke - ischemic", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}]}]}, {"title": "Stroke - hemorrhagic", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}]}]}, {"title": "Neurologic dysfunction", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}]}]}, {"title": "Psychiatric episode", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}]}]}, {"title": "Renal dysfunction", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}]}]}, {"title": "Respiratory failure", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}]}]}, {"title": "Right heart failure", "categories": [{"measurements": [{"groupId": "OG000", "value": "10"}]}]}, {"title": "Right heart failure w RVAD", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}]}]}, {"title": "Wound dehiscence", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "OG000", "value": "54"}]}]}]}, {"type": "SECONDARY", "title": "Device Malfunctions", "description": "Frequency and incidence of device malfunction", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of events", "timeFrame": "As they occurred, Baseline through 180 Days; Subjects that remain ongoing after 6 months will continue to be followed to 24 months post-implant or outcome", "groups": [{"id": "OG000", "title": "HeartMate 3", "description": "HeartMate 3 Left Ventricular Assist System (HM3 LVAS) used for advanced refractory left ventricular heart failure (50 Subjects in the Study Cohort)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"title": "Pump malfunctions", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Non-pump malfunction: internal component", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Non-pump malfunction: External components", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}]}]}]}, {"type": "SECONDARY", "title": "Reoperations", "description": "Frequency of reoperations", "populationDescription": "Twenty-nine (58%) did not have reoperation", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of re-operations by reason", "timeFrame": "As they occurred, Baseline through 180 Days", "groups": [{"id": "OG000", "title": "HeartMate 3", "description": "HeartMate 3 Left Ventricular Assist System (HM3 LVAS) used for advanced refractory left ventricular heart failure (50 Subjects in the Study Cohort)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"title": "Major bleeding", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}]}]}, {"title": "Cardiac arrhythmia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Pericardial fluid", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Major infection", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Respiratory failure", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}]}]}, {"title": "Right heart failure", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "Wound dehiscence", "categories": [{"measurements": [{"groupId": "OG000", "value": "15"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}]}]}]}, {"type": "SECONDARY", "title": "Rehospitalizations", "description": "Frequency and incidence of rehospitalizations", "populationDescription": "Number of Participants with Rehospitalizations According to Rehospitalization Type", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "As they occurred, Baseline through 180 Days", "groups": [{"id": "OG000", "title": "HeartMate 3", "description": "HeartMate 3 Left Ventricular Assist System (HM3 LVAS) used for advanced refractory left ventricular heart failure (50 Subjects in the Study Cohort)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}]}], "classes": [{"title": "Suspected device malfunction", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Transplant/ Transplant evaluation", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Anticoagulation maintenance", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Routine testing", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "ICD therapy", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Suspected driveline infection", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Bleeding", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}]}]}, {"title": "Infection", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}]}]}, {"title": "Neurologic dysfunction", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Arrythmia", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Volume issue", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}]}]}, {"title": "INR", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}]}]}, {"title": "Chest pain", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}]}]}]}, {"type": "SECONDARY", "title": "Stroke Free Survival", "description": "Percentage of participants free of debilitating stroke (Modified Rankin Score \\> 3)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "HeartMate 3", "description": "HeartMate 3 Left Ventricular Assist System (HM3 LVAS) used for advanced refractory left ventricular heart failure (50 Subjects in the Study Cohort)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "90"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From time of device implant to 6 months", "description": "Adverse events were documented by study site staff as they occurred per protocol definitions.", "eventGroups": [{"id": "EG000", "title": "HeartMate 3", "description": "Left Ventricular Assist System (LVAS) to be used on Subjects with advanced refractory left ventricular heart failure", "deathsNumAffected": 4, "deathsNumAtRisk": 50, "seriousNumAffected": 34, "seriousNumAtRisk": 50, "otherNumAffected": 34, "otherNumAtRisk": 50}], "seriousEvents": [{"term": "Bleeding", "organSystem": "General disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 19, "numAffected": 14, "numAtRisk": 50}]}, {"term": "Bleeding - Requiring Surgery", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 7, "numAtRisk": 50}]}, {"term": "Bleeding - Gastrointestinal", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 4, "numAtRisk": 50}]}, {"term": "Cardiac Arrhythmias - Ventricular", "organSystem": "Cardiac disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 50}]}, {"term": "Cardiac Arrhythmias - Supraventricular", "organSystem": "Cardiac disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 50}]}, {"term": "Pericardial Fluid", "organSystem": "Cardiac disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Internal Device Malfunction", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Pump Thrombosis", "organSystem": "Product Issues", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 50}]}, {"term": "External Device Malfunctions", "organSystem": "Product Issues", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Hemolysis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 50}]}, {"term": "Hepatic Dysfunction", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 50}]}, {"term": "Hypertension", "organSystem": "Cardiac disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 50}]}, {"term": "Any Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 11, "numAtRisk": 50}]}, {"term": "Infection - Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 50}]}, {"term": "Infection - Driveline", "organSystem": "Infections and infestations", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 50}]}, {"term": "Infection - Pump", "organSystem": "Infections and infestations", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 50}]}, {"term": "Myocardial Infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 50}]}, {"term": "Any Stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 50}]}, {"term": "Stroke - Ischemic", "organSystem": "Nervous system disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 50}]}, {"term": "Stroke - Hemorrhagic", "organSystem": "Nervous system disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 50}]}, {"term": "Neurologic Dysfunction", "organSystem": "Nervous system disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Psychiatric Episode", "organSystem": "Psychiatric disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 50}]}, {"term": "Renal Dysfunction", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 50}]}, {"term": "Respiratory Failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 8, "numAtRisk": 50}]}, {"term": "Right Heart Failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 50}]}, {"term": "Right Heart Failure - requiring RVAD", "organSystem": "Cardiac disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 50}]}, {"term": "Arterial Thromboembolism", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 50}]}, {"term": "Venous Thromboembolism", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 50}]}, {"term": "Wound Dehiscence", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 50}]}, {"term": "Other Serious Adverse Event", "organSystem": "General disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 24, "numAffected": 17, "numAtRisk": 50}]}], "otherEvents": [{"term": "Bleeding", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 5, "numAtRisk": 50}]}, {"term": "Cardiac Arrhythmias", "organSystem": "Cardiac disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 50}]}, {"term": "Cardiac Arrhythmias - Supraventricular", "organSystem": "Cardiac disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 10, "numAtRisk": 50}]}, {"term": "External Device Malfunction", "organSystem": "Product Issues", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 11, "numAtRisk": 50}]}, {"term": "Any infection", "organSystem": "Infections and infestations", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 7, "numAtRisk": 50}]}, {"term": "Neurologic Dysfunction", "organSystem": "Nervous system disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 50}]}, {"term": "Other Non-serious Adverse Event", "organSystem": "General disorders", "sourceVocabulary": "Protocol", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 36, "numAffected": 10, "numAtRisk": 50}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Poornima Sood", "organization": "St. Jude Medical", "email": "PSood@sjm.com", "phone": "+17818528334"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Czech Republic"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M12154", "name": "Cardiomyopathies", "relevance": "LOW"}, {"id": "M20824", "name": "Ventricular Dysfunction", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}